New onset somnambulism associated with different dosage of mirtazapine: A case report

Clinical Neuropharmacology

Volumn 32, Issue 4, 2009, Pages 232-233

  Yeh, Yi Wei ^a   Chen, Chun Hsiung ^a   Feng, Hui Ming ^b   Wang, Sheng Chiang ^a   Kuo, Shin Chang ^a   Chen, Chih Kang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Antidepressants; Mirtazapine; Sleepwalking; Somnambulism

Indexed keywords

MIRTAZAPINE;

ADULT; AROUSAL; ARTICLE; BEDTIME DOSAGE; BLOOD EXAMINATION; CASE REPORT; CONFUSION; DISEASE DURATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SLEEP WALKING; THYROID FUNCTION TEST; TREATMENT DURATION; URINALYSIS;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIANSERIN; SOMNAMBULISM;

EID: 68949194561     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318187bafc     Document Type: Article

References (16)

1. Ferrandiz-Santos JA, Mataix-Sanjuan AL. Amitriptyline and somnambulism. Ann Pharmacother 2000;34:1208.
2. Kawashima T, Yamada S. Paroxetine-induced somnambulism. J Clin Psychiatry 2003;64:483.
3. Khazaal Y, Krenz S, Zullino DF. Bupropion-induced somnambulism. Addict Biol 2003;8:359-362.
4. Guilleminault C, Kirisoglu C, Bao G, et al. Adult chronic sleepwalking and its treatment based on polysomnography. Brain 2005;128:1062-1069.
5. Hublin C, Kaprio J, Partinen M, et al. Prevalence and genetics of sleepwalking: a population-based twin study. Neurology 1997;48:177-181.
6. Pressman MR. Factors that predispose, prime and precipitate NREM parasomnias in adults: clinical and forensic implications. Sleep Med Rev 2007;11:5-30; discussion 31-33.
7. Shen J, Chung SA, Kayumov L, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry 2006;51:27-34.
8. Staner L, Kempenaers C, Simonnet MP, et al. 5-HT2 receptor antagonism and slow-wave sleep in major depression. Acta Psychiatr Scand 1992;86:133-137.
9. Chou YL, Stanley JT, Vujisic K, et al. Effects of systemic administration of mirtazapine on respiratory muscle activity in sleeping rats. Adv Exp Med Biol 2008;605:257-261.
10. Ruigt GSF, den Brok-Bardoel M, Ringens J. High and low doses of mirtazapine have different effects on rat sleep. Biol Psychiatry 1997;42:237S.
11. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285.
12. Juszczak GR, Swiergiel AH. Serotonergic hypothesis of sleepwalking. Med Hypotheses 2005;64:28-32.
13. Hughes JR. A review of sleepwalking (somnambulism): the enigma of neurophysiology and polysomnography with differential diagnosis of complex partial seizures. Epilepsy Behav 2007;1 1:483-491.
14. Munchau A, Langosch JM, Gerschlager W, et al. Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression. J Neurol Neurosurg Psychiatry 2005;76:527-533.
15. Juckel G, Schule C, Pogarell O, et al. Epileptiform EEG patterns induced by mirtazapine in both psychiatric patients and healthy volunteers. J Clin Psychopharmacol 2003;23:421-422.
16. Remulla A, Guilleminault C. Somnambulism (sleepwalking). Expert Opin Pharmacother 2004;5:2069-2074.